Biogennix Appoints Michael Roux General Manager

Irvine, California-based osteobiologics company Biogennix has named Michael Roux its new General Manager.

Biogennix is a developer, manufacturer, and distributor of bone graft substitutes for bone fusion procedures. Its osteobiologic products are specifically designed for posterolateral spine fusion.

Roux is joining Biogennix after almost 30 years of experience in the technology and medical device space. Roux previously led product management at Glidewell Laboratories, a dental technology company. He also served as Vice President of Product Management with Patient Safety Technologies, before its acquisition by Stryker Corporation in 2014. Roux also served as Global Director at Hill-Rom and 3M, where he worked in product engineering, six-sigma, global product marketing, and business development.

Clay Shors, president of Biogennix, said that Roux “has a strong background in product management and marketing with a wide range of medical device and multi-national business expertise with leading publicly owned and privately held companies. We look forward to reaping the benefits of his ability to consistently deliver bottom line results in entrepreneurial to large scale global businesses through strategic thinking, data driven decision making, innovative problem solving, effective team building and leadership.”

Shors noted that Biogennix expects to continue its exponential growth with the addition of Roux, the recent expansion of the sales and marketing initiatives, and the hiring of key team members in sales, marketing, and R&D.

Michael Roux told OTW that he was excited to be joining the Biogennix team. He said, “Biogennix has great momentum coming into 2019 after another strong growth year, and I’m very excited to be joining the team. Our Morpheus and osteoSPAN bone graft products continue to fuel our growth, and with our new team members and enhanced strategies for 2019, we’re on pace to build on past success with products that are fast becoming the new standard of effectiveness and ease of use in the bone graft substitute space.”